IO Frontiers World 2019


Greg Bonfiglio

Greg Bonfiglio

Founder & Managing Partner, Proteus, LLC
Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC – an investment and advisory firm focused solely on regenerative medicine.  Proteus provides fund management and consulting services to the regenerative medicine industry.   Proteus works with RM companies across all stages of development from early stage to large pharma, as well as governmental entities pursuing RM initiatives.        
Mr. Bonfiglio is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine (RM Translation Center in Toronto, Canada).   Mr. Bonfiglio has served on the Boards of several RM companies, including VistaGen Therapeutics (in vitro tools from hESCs); California Stem Cell (hESC tools & therapeutics); and StemCyte, Inc. (cord blood storage & therapeutics).
Mr. Bonfiglio was an early investor in the field of stems cell & regenerative medicine, and he continues to be actively involved in the field.  He is a frequent speaker at Regenerative Medicine Conferences.  Mr. Bonfiglio is a Member of the ISSCR and is on their Advisory Board, as well as their Finance Committee.  He also is a Member of the ISCT and ARM.  In 2013, Mr. Bonfiglio was listed among the Top 50 Stem Cell Influencers in the world (Ranked 14th).  
Mr. Bonfiglio has over 25 years experience working with technology companies.    From 2000 – 2005, Mr. Bonfiglio was a General Partner with Anthem Venture Partners – an early stage venture fund in California.    While at Anthem, Mr. Bonfiglio led investments in both biotechnology and IT.  Anthem generated top quartile returns for its investors.  
Prior to joining Anthem, he was a Partner with Morrison & Foerster, where he worked extensively with technology clients.   Mr. Bonfiglio was an Adjunct Professor of Law at Stanford Law School, from 1996 to 2000.  He has been a Guest Lecturer at the Stanford Business School on the Commercialization of RM Technologies.  From 1995 -2005, he was a regular Guest Lecturer at the UC Berkley Haas Business School in the Entrepreneurship Program.     
Mr. Bonfiglio received his B.A. in Mathematics (magna cum laude) from Michigan State University in 1975, and his J.D. (magna cum laude) from the University of Michigan Law School in 1981.   
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy